Tissue transglutaminase induces epithelial-mesenchymal-transition and the acquisition of stem cell like characteristics in colorectal cancer cells by Ayinde, Oluseyi et al.
Oncotarget20025www.impactjournals.com/oncotarget
Tissue transglutaminase induces Epithelial-Mesenchymal-
Transition and the acquisition of stem cell like characteristics in 
colorectal cancer cells
Oluseyi Ayinde1, Zhuo Wang1, Martin Griffin1
1School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom
Correspondence to: Martin Griffin, email: M.Griffin@aston.ac.uk
Zhuo Wang, email: wangz8@aston.ac.uk
Keywords: tissue transglutaminase, Epithelial-Mesenchymal Transition, cancer stem cells, colorectal cancer
Received: September 26, 2016    Accepted: January 07, 2017    Published: February 16, 2017
ABSTRACT
Human colon cancer cell lines (CRCs) RKO, SW480 and SW620 were investigated 
for TG2 involvement in tumour advancement and aggression. TG2 expression 
correlated with tumour advancement and expression of markers of epithelial-
mesenchymal transition (EMT). The metastatic cell line SW620 showed high TG2 
expression compared to the primary tumour cell lines SW480 and RKO and could form 
tumour spheroids under non- adherent conditions. TG2 manipulation in the CRCs by 
shRNA or TG2 transduction confirmed the relationship between TG2 and EMT. TGFβ1 
expression in CRC cells, and its level in the cell medium and extracellular matrix 
was increased in primary tumour CRCs overexpressing TG2 and could regulate TG2 
expression and EMT by both canonical (RKO) and non-canonical (RKO and SW480) 
signalling. TGFβ1 regulation was not observed in the metastatic SW620 cell line, but 
TG2 knockdown or inhibition in SW620 reversed EMT. In SW620, TG2 expression 
and EMT was associated with increased presence of nuclear β-catenin which could 
be mediated by association of TG2 with the Wnt signalling co-receptor LRP5. TG2 
inhibition/knockdown increased interaction between β-catenin and ubiquitin shown 
by co-immunoprecipitation, suggesting that TG2 could be important in β-catenin 
regulation. β-Catenin and TG2 was also upregulated in SW620 spheroid cells enriched 
with cancer stem cell marker CD44 and TG2 inhibition/knockdown reduced the 
spheroid forming potential of SW620 cells. Our data suggests that TG2 could hold 
both prognostic and therapeutic significance in colon cancer.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer in the world and a major cause of morbidity 
and mortality [1]. Although advances have been made 
in the treatment of CRC over the last decade with the 
introduction of new surgical techniques, radiotherapy 
and chemotherapy, the overall survival rate of patients 
with CRC has not shown a marked improvement [2]. 
Survival of the disease is highly dependent upon the stage 
of disease at diagnosis, and typically ranges from a 90% 
5-year survival rate for cancers detected at the localized 
stage, 70% for regional, 10% for people diagnosed for 
distant metastatic cancer [3]. Metastasis plays a critical 
role in the poor prognosis, and more than one-third of 
patients with CRC will ultimately develop metastatic 
disease [4].
The bulk of carcinoma cells generally exhibit a 
predominance of epithelial characteristics. However, 
in order to invade, disseminate to distant tissues and 
subsequently form metastatic colonies, neoplastic 
epithelial cells must shift, at least transiently, into a more 
mesenchymal phenotype. Epithelial-Mesenchymal-
Transition (EMT) is a physiological process found in 
embryonic development, tissue remodelling and wound 
healing [5]. In neoplasms it is a critical step in the 
progression of tumour cells from in situ carcinoma to 
distant metastasis. Furthermore, recent reports suggest that 
EMT results in the acquisition of other properties involved 
in carcinoma progression, such as increased resistance 
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to apoptosis, drug resistance, increased motility and the 
acquisition of stem cell-like properties [6].
The multifunctional enzyme tissue transglutaminase 
(TG2) is a protein involved in a number of cellular roles, 
including the post translational modification of proteins, as 
a scaffold protein in cell adhesion and as a cell signalling 
protein [7-9]. TG2 also acts as an important part of a 
pro-inflammatory response and has been associated with 
EMT in both fibrosis and cancer [10]. TG2 is associated 
with various physiological and pathological conditions 
[11]. Clinical studies have correlated TG2 expression 
with metastatic cancer and poor survival outcomes of 
ovarian, breast and colon cancer patients [12, 13]. It is 
also suggested that TG2 mediates several aspects of cancer 
cell behaviour, including motility, invasion, growth, and 
survival [11, 14, 15]. Although recent studies in different 
cancer cell types suggest a role for TG2 in EMT as 
highlighted by a possible cross talk between TG2 and 
three critical pathways in EMT, e.g. Transforming Growth 
Factor β 1 (TGFβ1), Wnt, β-catenin and Nuclear factor 
kappa light chain enhancer of activated B (NFκB) [16, 
17], there still remain a number of conflicting reports on 
the importance of TG2 in cancer progression with respect 
to its pro and/or anti-cancer roles [18-22]. This may in part 
be accounted for by the pleiotropic nature of TG2 owing to 
its multifunctional roles [19].
Using the well characterised human colorectal 
cancer cell lines RKO, SW480 and SW620 as a well-
validated model [23] for the in vitro study of colorectal 
cancer progression we show that TG2 expression 
correlates with disease progression. We also show that 
knockdown or inhibition of TG2 results in the reduced 
ability of CRCs to acquire a mesenchymal and stem cell 
like phenotype. We also show, dependent on the cell line, 
that TG2 plays an important role in multiple pathways in 
the induction of EMT.
RESULTS
TG2 expression correlates with disease 
progression in this CRC model
TG2 expression was determined in cell lysates of 
three well characterised colon cancer cell lines RKO, 
SW480 and SW620, via Western blotting. RKO and 
SW480 are primary human CRC cell lines, while SW620 
is a lymph metastatic cell line. SW480 and SW620 are 
an isogenic pair obtained from the same patient and 
serve as an in vitro model for tumour progression [23]. 
Figure 1A shows that TG2 expression was increased 
in the metastatic cell line SW620 compared to the two 
primary cancer cell lines SW480 and RKO with more 
TG2 expressed in SW480 compared to RKO cells. This 
difference in TG2 expression followed a similar trend 
when levels TG2 activity were measured in the different 
cell lines (Figure 1B).
TG2 is required for EMT in this CRC model
TG2 expression was silenced in SW480 and 
SW620 cells by transduction of cells with TG2 shRNA. 
The efficiency of the different shRNA constructs on TG2 
expression and corresponding effect on the expression 
of EMT markers are shown in Supplementary Figure 1. 
In RKO cells where TG2 basal levels are low, cells were 
transduced with the wild type TG2. Comparison of TG2 
expression with the expression of EMT markers in the 
different cells (Figure 1C) shows that increase in TG2 
expression by viral trasduction in RKO cells leads to 
increased expression of mesenchymal markers, including 
vimentin and FN, and a decrease in epithelial tight junction 
marker Zonal occludin 1 (ZO-1). The expression level of 
these markers was reversed once TG2 was downregulated 
by transduction of TG2 shRNA in SW480 cells. Only the 
metastatic SW620 cells express detectable mesenchymal 
markers, including N-cadherin, S100A4 and α smooth 
muscle actin (αSMA). TG2 downregulation by shRNA 
leads to reduced mesenchymal markers FN, vimentin 
and N-cadherin and restored levels of ZO-1 (Figure 1C). 
These changes in EMT markers with TG2 expression were 
validated in SW620 cell by immunofluorescence staining 
of Vimentin, Fibronectin (FN) and ZO-1 (Figure 1D). 
We next investigated the impact of TG2 on the upstream 
events of EMT by determining the level of expression of 
the transcription factors Slug and Twist1. Figure 2A shows 
that knock down of TG2 in the high TG2 expressing 
SW620 cells results in a significant decrease in both Slug 
and Twist, suggesting that TG2’s role in EMT is upstream 
of these two transcription factors in the EMT process.
Treatment of SW620 and SW480 (Figure 2B and 
2C) with the TG2 selective inhibitor 1-155 [24-26] also 
reduced the expression of TG2 and EMT markers— 
vimentin and FN in SW480 and SW620 cells, and the 
expression of transcription factors Slug and Twist 1 in 
SW620 cells. 1-155 treatment also enhanced expression 
of the epithelial marker ZO-1 in both cell lines. Similarly, 
in the TG2 transduced RKO cells, treatment with TG2 
inhibitor 1-155 reduced expression of the EMT marker 
FN and upregulated ZO-1, compared to control TG2- 
transduced RKO cells, while TG2 expression by Lentiviral 
transduction was not affected by 1-155 treatment 
(Figure 2D).
Manipulating TG2 expression in RKO, SW480 and 
SW620 also altered the morphology of these cells (Figure 
2E). Increased TG2 expression led to an elongated, 
fibroblast like appearance in cells, while loss of TG2 
expression led to a more cuboidal, more epithelial cell like 
morphology.
TGFβ1 induces TG2 and EMT in CRCs
In CRCs, TGFβ1 signalling, an inducer of EMT, 
can be a major dysfunctional point during tumour 
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Figure 1: TG2 expresssion correlates with disease progression and EMT. A. Western blotting of whole cell lysates from wt 
RKO, SW480 and SW620 cells showing expression of TG2, EMT and disease severity markers. SDS-PAGE and Western blotting were 
carried out as described in the Materials and Methods. B. TG2 activity measured in whole cell lysates of wt RKO, SW480 and SW620 cells 
undertaken as described in the Materials and Methods. p<0.05, *, significant from SW480, **, significant from RKO. Data are represented 
as mean ± S.D, (n=3). C. Western blotting for TG2 and EMT markers in CRCs with TG2 expression increased by viral transduction (TG2) 
or reduced by transduction with TG2 shRNA (SW480shRNA and SW620shRNA) and their corresponding transduced empty vector (EV) 
controls. D. Immunofluorescent detection of TG2 and EMT marker epitopes by fluroscence microscopy in TG2 manipulated cells and their 
corresponding controls (EV). Representative image from two independent experiment.
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Figure 2: Manipulation of TG2 expression or activity correlates with EMT markers. A. Western blot showing that TG2 
expression correlates with increased expression of transcription factors of EMT(Slug and Twist) in SW620 (EV) control cells or SW620 
cells transduced with TG2 shRNA (shRNA). B. Western blot of whole cell lysates from SW620 control cells and SW620 cells transduced 
with TG2 shRNA or control EV cells treated with TG2 selective inhibitor 1-155 (1 µM). Control cells were treated with vehicle alone 
DMSO. C. Western blot of SW480 control cells and SW480 cells transduced with TG2 shRNA (SW480shRNA) or wt cells treated with 
TG2 selective inhibitor 1-155 (1 µM). Control EV cells were treated with vehicle alone DMSO. D. RKO EV cells treated with the vehicle 
control DMSO or TG2 selective inhibitor 1-155 (1 µM) and RKO cells transduced with TG2 (RKOTG2). E. Representative images of 
cell morphology of CRCs transduced with TG2 shRNA or wt TG2. Equal number of cells were seeded and 48 h images were taken at 40× 
Objective magnification.
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progression [1]. Figure 3A shows that TGFβ1 expression 
correlates with TG2 expression in the whole cell lysates 
of RKO and SW480 when TG2 is either increased or 
decreased, respectively, which is comparable to the 
levels TGFβ1 found in the cell culture medium (Figure 
3B). Moreover, TG2 inhibition by 1-155 results in 
reduced expression of TGFβ1 in whole cell lysates and 
in matrix bound TGFβ1 in primary tumour CRCs RKO 
and SW480 (Figure 3D). We demonstrate that the cell 
surface activity of TG2 (Figure 3E) in these cell lines also 
correlates with the presence of TGFβ1 in the extracellular 
milieu, suggesting a link between cell surface TG2 and 
Extracellular Matrix (ECM) bound TGFβ1. Interestingly, 
in SW620 cells, TGFβ1 levels show no correlation with 
TG2 expression (Figure 3B).
All the CRCs express TGFβ1 receptor I and II 
(Figure 4A) and the downstream signalling molecules 
Smad2/3. When treated with TGFβ1, EMT was induced 
in the RKO and SW480 cells with increased levels of 
vimentin and FN and decreased ZO-1 (Figure 4B). TGFβ1 
neutralising antibody treatment reduced expression of 
these EMT markers. The effect of TGFβ1 is confirmed 
by appearance of a fibroblast like phenotype in TGFβ1 
treated RKO and SW480 cells (Figure 4C). Figure 4D 
shows TG2 expression was increased by TGFβ1 treatment 
in RKO and SW480 cells with a corresponding increase in 
the phosphorylation of Smad2/3 shown in all CRC’s which 
could be reduced by the neutralising TGFβ antibody. 
However, neither TGFβ1 treatment nor TGFβ neutralizing 
antibody showed any effect on TG2 expression in SW620 
cells.
TGFβ1 induces EMT in primary CRCs RKO 
and SW480 via a non-canonical extracellular 
signal regulated kinase (ERK) pathway
The data obtained for TGFβ1 with RKO and SW480 
cells suggests a link between TGFβ1 signalling and TG2 
expression. However, since SW480 is a Smad4 null cell 
line and RKO expresses wild type Smad4 [27, 28], we 
next studied whether a potential Smad4-independent 
pathway in the SW480 cells which may also play a role 
in RKO cells is involved in inducing TG2 expression and 
EMT. TGFβ1 has been shown to mediate the activation of 
a number of downstream targets. In both cell lines, ERK 
phosphorylation was increased above background between 
30-120 min following TGFβ1stmulation (Figure 5A). 
Furthermore, inhibition of ERK1/2 by ERK1/2 inhibitor 
PD98059 reduced TG2 expression even in the presence of 
TGFβ1 when compared to the control cells (Figure 5B), 
suggesting that TGFβ1 may also employ the Mitogen 
activated protein kinase (MAPK) pathway for induction 
of TG2 in both RKO and SW480 cells.
It has been reported that ERK signalling can induce 
C-Jun [29]. In Figure 5C, we show that PD98059 reduced 
the expression of C-Jun with a corresponding decrease in 
TGFβ1 expression, indicating the involvement of C-Jun in 
ERK1/2-induced TGFβ1 expression in RKO and SW480 
cells. We also show that knockdown (SW480) or increase 
(RKO) in expression of TG2, or treatment with the 
selective inhbitor 1-155 results in reduced phosphorylation 
of ERK1/2 (Figure 5D and 5E).
TG2 induces EMT via multiple mechanisms in 
the different colon cancer cell lines
Since TGFβ1 does not impact on EMT in the 
metastatic SW620 cells despite TG2’s ability to induce 
EMT in these cells (Figure 4B and 4C), we looked at the 
potential involvement of the Wnt/β-catenin signalling 
pathway and key integrins, through which TG2 could 
be involved in driving EMT. SW620 is rich in the TG2 
binding receptor Low-density lipoprotein receptor-related 
protein 5 (LRP5), but shows very little expression of β1 
Integrin (Figure 6A). Importantly, we show that in SW620, 
knock down of TG2 expression by shRNA leads to the 
reduction of the translocation of β-catenin into the nucleus 
(Figure 6B and 6C). By using co-IP, we demonstrate that 
TG2 interacts with β-catenin which can be reduced by the 
TG2 selective inhibitor 1-155 (Figure 6D and 6E). We also 
confirm by co-IP that TG2 binds to LRP5 (Figure 6D), a 
co-receptor with frizzle and LRP6 in the propagation of 
Wnt signalling [30]. This interaction can be reduced in 
cells treated with TG2 inhibitor 1-155 (Figure 6D).
Figure 6F shows via co-IP, that β-catenin interaction 
with ubiquitin is increased when cells are treated with 
TG2 inhibitor 1-155 when compared to control cells. 
Interestingly, in SW620 cells neither TG2 knockdown 
nor inhibition with 1-155 altered the interaction between 
β-catenin and Src (Figure 6G), suggesting that TG2 is able 
to inhibit ubiquitination of β-catenin, downstream of Src 
in SW620 cells.
Colon cancer stem cells express TG2 and 
β-catenin
Unlike RKO and SW480 cells which were unable 
to form compact spheres, the metastatic cell line SW620 
proliferates and forms compact spheroids (Figure 7A) in 
non-adherent cell culture. Figure 7B shows representative 
images of the formation of SW620 spheroids in this type 
of cell culture over fifteen days. Surviving cells proliferate, 
aggregate and eventually form compact spheroids with a 
dense core observed after 15 days. Given these differences 
in spheroid formation, we looked at the clonogenic ability 
of RKO, SW480 and SW620 on soft agar (Figure 7C). 
Metastatic SW620 cells readily formed colonies compared 
to primary cells SW480 and RKO. Comparison of the 
SW620 spheroids to the parental SW620 cells cultured in 
adherent conditions (Figure 8A) shows that the spheroids 
from SW620 cells express increased levels of the stem 
cell marker CD44, compared to parental cells, suggesting 
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the spheroids are enriched with stem cell like cells. In 
addition, both TG2 and β-catenin are over expressed in 
the SW620 spheroids. We next attempted to determine the 
importance of TG2 in the enrichment of stem cells and 
clonogenicity. In Figure 8B and 8C, both TG2 knockdown 
and TG2-specific inhibitor 1-155 (1 µM) treatment 
significantly reduced the spheroid forming potential of 
SW620 as measured by cell viability of the spheroids. 
TG2 knockdown or inhibition also significantly reduced 
the clonogenic ability of SW620 cells.
Figure 3: TG2 induces TGFβ1 expression and release into cell culture media. A. Western blots of whole cell lysates of CRCs 
showing increased expression of TGFβ1 in whole cell lysates of RKO EV control cells, RKO transduced with TG2 (RKOTG2), SW480 or 
SW620 transduced with empty vectors (EV) cells or transduced with TG2 shRNA (shRNA). B. TGFβ1 released into cell culture media of 
CRCs determined by ELISA undertaken as described in the Materials and Methods. Data represent means ± S.D., from two experiments 
each performed in triplicate (*, **, # and ~, p<0.05). C. Representative Dot blotting of cell culture media of CRCs both EV controls and 
cell transduced with TG2 (TG2) or shRNA (SW480shRNA and SW680shRNA), and recombinant human TGFβ1 probed with TGF β1 
antibody (n=3). D. Western blot of total TGFβ1 expression in whole cell lysate and in ECM fractions of CRCs wt RKO (treated with 
DMSO control) and wt SW480 cells folllowing treatment with TG2 cell permeable inhibitor 1-155 (1 µM). E. Cell surface TG2 activity 
measured by incorporation of biotin-X-cadavarine in RKO EV control cells, RKOTG2 cells, SW480 EV control cells and SW480shRNA 
cells measured as described in the Materials and Methods. Data are represented as mean ± S.D., (n=2), with each independent experiment 
performed in triplicate (* and #, p<0.05).
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Figure 4. TGFβ1 induces EMT and TG2 in primary CRCs RKO and SW480. A. Western blotting of CRCs showing presence 
of TGFβ receptor (TGFβR) I and TGFβRII in wt RKO, SW480 and SW620 whole cell lysates. B. Western blotting of whole cell lysates 
of wt CRCs RKO, SW480 and SW620. Cells showing presence or absence of EMT markers following TGFβ1 treatment with and without 
treatment with TGFβ neutralising antibody. C. Representative images of cell morphology of CRCs wt RKO and SW480 treated with 
rhTGFβ1 (2.5 ng/ml) and rhTGFβ1 plus TGFβ1 neutralising antibody PAN (20µg/ml). Equal numbers of cells were seeded and 48 h after 
treatment images were taken at 20× objective using a phrase contrast microscope. D. Western blot of whole cell lysates from wt RKO, 
SW480 and SW620 cells, showing expression of TG2 after TGFβ1 treatment, with or without treatment with TGFβ neutralising antibody. 
CRCs were treated with human recombinant TGFβ1 (2.5 ng/ml) and TGFβ neutralising antibody (NA) (20 µg/ml) for 48 h.
Oncotarget20032www.impactjournals.com/oncotarget
Figure 5: ERK1/2 plays a role in TGFβ1 induced TG2, and TG2 induced TGFβ1 expression in RKO and SW480 cells. 
A. Western blotting showing ERK1/2 activation, after TGFβ1 (5.0 ng/ml) treatment over a time course of 2 h in wt RKO and SW480 
cells. B. Western bloting of whole cell lysates of wt RKO and SW480 cells, showing expression of TG2 and ERK1/2 after treatment with 
TGFβ1 with or without ERK inhibitor PD98059 (10 μM). C. Western blotting of whole cell lysates from wt RKO and SW480 cells showing 
expression of ERK1/2, C-Jun and TGFβ1 with or without treatment of cells with ERK inhibitor PD98059 (10 μM). D. Western blotting of 
whole cell lysates of RKO and SW480 control cells and cells transduced with TG2 (RKOTG) or shRNA (SW480shRNA), showing TG2 
expression, ERK1/2 activation and TGFβ1 expression. E. Western blotting of whole cell lysates showing activation of ERK1/2 in wt RKO 
and SW480 cells with or without treatment with TG2-sepcific cell permeable inhibitor 1-155 inhibitor (1 μM).
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Figure 6: TG2 interacts with LRP5 prevents ubiquitination of β-catenin and induces β-catenin accumulation in the 
nucleus. A. Western blotting of whole cell lysates of SW620 EV control cells and SW620 transduced with TG2shRNA (SW620shRNA), 
showing expression of TG2, LRP5, β1 Integrin, phosphorylated and total Src. B. Western blotting of β-catenin presence in the nuclear 
(N) and cytoplasmic (C) in cell extracts of SW620 control cells and SW620shRNA cells. LDH and Lamin A were used as cytoplasmic 
and nuclear protein markers respectively. The N and C fractions were separated as described in the Materials and Methods. C. Western 
blotting of β-catenin expression in whole cell lysates of SW620 control cells and SW620shRNA cells. D. Western blotting of LRP5 and 
β-catenin in wt SW620 treated with DMSO (control) and SW620 cells treated with TG2 selective inhibitor 1-155 (1 µM), following TG2 
co-IP from whole cell lysates. PBS containing no cell lysates was used as the negative control sample. Co-IP was undertaken as described 
in the Materials and Methods. E. Western blotting of whole cell lysates for TG2 after β-catenin co-IP, following treatment of cells with 
TG2-selective inhibitor 1-155 (1 µM) or DMSO control. PBS containing no cell lysates was used as the negative control sample. F. Western 
blotting of whole cell lysates from wt SW620 cells after treatment with TG2 selective inhibitor 1-155 (1 µM) or DMSO control, showing 
β-catenin after ubiquitin co-IP of whole cell lysates from wt SW620. PBS containing no cell lysates was used as the negative control 
sample. G. Western blotting of β-catenin after Src co-IP from whole cell lysates of SW620 EV cells (treated with DMSO) and SW620 
shRNA cells or after treatment with TG2 inhibitor 1-155. PBS containing no cell lysates was used as the negative control sample.
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DISCUSSION
Our previous work using the CT26 mouse CRC 
cells indicated the relationship between TG2 expression, 
TGFβ1 and FN deposition in colon cancer [19]. In 
this manuscript, we assess the role of TG2 in disease 
progression using the 3 well-characterised human CRC 
cell lines RKO, SW480 and SW620. The level of TG2 
expression in these cell lines is associated with disease 
progression from primary (RKO and SW480) to metastatic 
(SW620), in agreement with earlier clinical studies [12, 
13]. We show that high TG2 expressing SW620 cells 
express low levels of the epithelial marker ZO-1, but 
increased levels of mesenchymal markers N-cadherin, 
α-SMA and protein S100A4 which is associated with 
metastatic disease [11]. This is in contrast to the less 
progressive primary tumour cells SW480 and RKO which 
show lower levels of TG2 expression and much lower 
levels of EMT markers suggesting a potential prognostic 
role for TG2 in colon cancer. This finding agrees with 
the study by Miyoshi et al. [31] and Yang et al. [32] who 
showed that TG2 expression was higher in colon cancer 
tissue compared to the corresponding normal tissue. 
Similarly, a recent study by Fernandez-Acenero et al. 
[33] showed that TG2 expression in the epithelia of colon 
carcinomas was significantly associated with poor patient 
survival, and tumour metastasis. Importantly recent work 
by Mouradov et al. [34] using human colorectal cancer 
lines has shown that CRC cell line such as these used 
in this study are representative of the main subtypes of 
primary tumours at the genomic level, validating their 
use as tools to investigate colorectal cancer biology and 
responses to new potential drugs.
EMT is important during cancer progression and is 
the initial step in tumour metastasis and linked to drug 
resistance [35-37] and the acquisition of cancer stem cell 
like properties [10, 17, 38]. Studies have shown that TG2 
influences EMT in both cancer and fibrosis [36, 27, 39]. 
Here we show that knock down of TG2 expression in 
SW480 and SW620 cells leads to decreased expression of 
EMT markers and increased expression of the epithelial 
marker ZO-1, confirming the importance of TG2 in 
tumour progression via enhancing EMT. This agrees 
with previous studies in breast, ovarian, pancreatic, renal 
carcinomas and gliomas which show that TG2 plays a role 
in inducing EMT [8]. Our cell-permeable TG2-selective 
inhibitor 1-155 was able to attenuate EMT in these cells. 
There are two mechanisms for the impact of 1-155 on 
TG2, the inhibition of TG2 crosslinking activity and 
induction of conformational changes by locking of the 
enzyme into an open conformation which blocks GTP 
binding and alters interactions with other key proteins 
[24]. Therefore, it is highly possible that either or both of 
these effects could be responsible for inhibiting the role 
of TG2 in inducing EMT in these cells. The finding that 
TG2 inhibition reduces Slug and Twist expression in the 
metastatic SW620 cells also confirms that TG2 is acting 
upstream of these transcription factors as previously found 
in MCF10A and MCF12A cells [37].
Aberrations occurring in the TGFβ1 and Wnt/β-
catenin signalling pathways have both been implicated 
in EMT and tumour progression [1, 40]. It is also well 
reported that TGFβ1 can specifically induce TG2 
expression [26], which we have confirmed in RKO 
and SW480 cells. Importantly, the specific effects of 
TGFβ1 on TG2 induction could be blocked by a TGFβ 
neutralizing antibody in these two cell lines. Similarly, 
our results show that TGFβ1 can induce EMT in RKO 
and SW480, suggesting that TG2 is a downstream target 
of TGFβ1 and is recruited by TGFβ1 to induce EMT. 
However increasing the expression of TG2 in SW480 did 
not significantly change the expression of EMT markers 
and further treatment with TGFβ1 did not induce anymore 
EMT compared to control nontreated TG2 transduced cells 
(Supplementary Figure 2A and 2B). This may explain 
some of the findings in the metastatic SW620 where TG2 
expression is much higher, and TGFβ1 does not impact 
EMT, suggesting a more intrinsic mechanism for TG2 that 
is independent of growth factors or the ECM. Hence while 
the interplay between TG2 and TGFβ1 may be necessary 
to acquire a metastatic potential, further cellular mutations 
may be required for a metastasis with an increased but 
different role for TG2 in EMT which we observe in the 
SW620 cells.
The mechanism of TG2 induction by TGFβ1 in 
cells may be varied and cell specific. TGFβ1 was reported 
to upregulate TG2 in ovarian cancer by upregulating 
the activity of NFκB [17] and via the ERK and PI3/
AKT pathway in diseased pulmonary fibroblast [41]. 
Furthermore, genomic studies on TGFβ-regulated gene 
expression profiles also suggest that in the human lung 
cancer cell line A549, TGFβ1 induces TG2 expression 
by a pathway that is partially dependent on the ERK 
signalling pathway [42]. Hence, in this study we show 
that ERK1/2 a downstream signalling molecule in the Ras/
MAPK kinase pathway is activated in response to TGFβ1 
in both primary CRCs RKO and SW480, suggesting 
a potential role for ERK1/2 in TGF β1-induced TG2 
expression. We also show that TG2 was associated with 
increased expression and levels of TGFβ1 in the whole 
cell lysates and culture medium respectively. This agrees 
with our previous studies in murine colon carcinomas that 
showed increased levels of TGFβ1 in the medium of TG2 
transfected clones, which was inhibited by the inclusion 
of site-directed TG2 inhibitors in the culture medium 
[19]. It has been suggested by others that the MAP kinase, 
ERK1/2 signalling pathway may result in activation of 
Activator protein-1 (AP-1), a transcription factor which 
is critical for auto-induction of TGFβ1 [43]. Here we 
show that TG2 increases the activation of ERK1/2 
which can be reversed by silencing TG2 or by selective 
TG2 inhibition using 1-155. It is, therefore, plausible 
Oncotarget20035www.impactjournals.com/oncotarget
to suggest that activated ERK1/2 can induce c-Jun and 
in turn recruit transcription factor AP-1 for increased 
expression of TGFβ1. This is suggested by the increased 
expression of c-Jun in ERK1/2 activated SW480 and TG2 
transduced RKO cells. Furthermore, TG2 can increase 
the bio-availability of TGFβ1 in the ECM, increasing the 
potential for the release of active TGFβ1 from the large 
latent TGFβ1 binding complex [14]. Alternatively, active 
TGFβ1 crosslinked into the matrix might be necessary 
to enhance and stabilise the signalling potential of this 
growth factor as suggested by Griffin and colleagues [26]. 
Taken together these effects suggest a continuous loop and 
mechanism, in which TGFβ1 directly, or indirectly induces 
TG2 via ERK1/2, and TG2 via mediating activation of 
Figure 7: Metastatic SW620 cells form spheroids in non adherent cell culture. A. Spheroid formation in vitro, wt primary cells 
SW480 and RKO form loose aggregates, while wt metastatic SW620 cells proceed to form compact spheroids. Representative images were 
taken after 12 days of culture. B. Stages of spheroid formation in wt SW620 cells allowed to grow for 15 days. Compaction of spheroids is 
observed from 5 days with the precense of a dense core in the spheroid 15 days into the culture. Spheroids formation was captured at 20× 
objective days 3, 5, 7 and 10× Objective Day 15. C. Soft Agar colony formation assay for CRCs. Colonies were allowed to grow for 14 days, 
and then stained with crystal violet. Representative images of colony formation on soft agar (top panel) at 10× Objective magnification.
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Figure 8: TG2 and β-catenin promotes cancer stem cell formation in CRC SW620. A. Representative images taken at 10× 
magnification of wt SW620 monolayer and SW620 spheroid cells. Western blotting of wt SW620 monolayer and spheroid cells detecting 
the presence of TG2, stem cell marker CD44 and β-catenin expression in whole cell lysate. B. TG2 knockdown (SW620shRNA) or TG2 
inhibition (by 1 µM 1-155) reduces the enrichment of spheroids with stem cell like phenotype. For treatment group, CRCs were seeded in 
spheroid forming media contain 1 µM TG2 selective inhibitor 1-155 for 10 days, then spheroid images were captured and cell viability was 
performed using XTT. Data in the histogram are represented as mean ± S.D. n=3;*, # p<0.05; NS, not significant. C. Soft Agar formation 
assay for SW620 cells 14 days after seeding cells, colonies were stained with crystal violet. Colony number was determined by counting 
the amount of spheroids formed using a 10× objective over 10 different fields per well using a phase contrast microscope. D. Schematic 
showing extracellular TG2 interaction with LRP5 in the propagation of Wnt signalling. Cytosolic TG2 interaction with β-catenin inhibits 
ubiquitination of β-catenin allowing for cytosolic accumulation and nuclear translocation of β-catenin where it interacts with lef-2/TCf 
transcription factors to regulate cell renewal, EMT and cell cycle progression.
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ERK1/2 recruits the necessary machinery for increased 
TGFβ1 expression and secretion, thus sustaining EMT.
However, a role for TGFβ in EMT was not found in 
the metastatic cell line SW620. We, therefore, looked for 
alternative pathways that might be used by TG2 in driving 
EMT in SW620 cells. β-catenin is a known transcriptional 
regulator with oncogenic activity attributed to either 
activating mutation or interactions with mutated β-catenin 
interacting proteins [44], or by canonical activation of 
Wnt signalling. In carcinomas, β-catenin degradation 
is often blocked by either loss-of-function mutations of 
Adenomatous Polyposis Coli (APC) or by β-catenin 
mutations that render β-catenin stable [45]. In SW620 
cells, β-catenin is over expressed and stabilised due to 
mutations in APC [46]. We demonstrate that TG2 is able 
to interact with LRP5, a Wnt co-receptor in SW620 cells 
which can be reduced by the TG2-selective inhibitor 1-155 
which can also lock TG2 in its inactive open conformation 
[35]. This suggests that TG2-LRP5 interaction may be 
necessary to stabilise β catenin in these cells. TG2 may 
also stabilise β-catenin intracellularly since SW620 cells 
already possess loss or mutation in APC leading to loss of 
the glycogen synthase kinase-APC-Axin death complex, 
which induces proteosomal degradation of β-catenin. 
We show that interaction between TG2 and β-catenin is 
lost on TG2 inhibition by 1-155, thus allowing β-catenin 
association with ubiquitin. Our results also suggest that 
TG2 stabilisation of β-catenin is independent of Src in 
SW620, since neither knockdown nor inhibition of TG2 
resulted in reduced Src activation, or reduced interaction 
between Src and β-catenin. However, in RKO and 
SW480 cells, TG2 did induce increased phosphorylation 
of Src (Supplementary Figure 3). In ovarian carcinomas 
TG2 recruits Src via activation through β1-integrin 
and FN interaction for the stabilisation of β-catenin 
[44]. Interestingly, in the SW620 cells, β1-integrin was 
poorly expressed. Therefore, Src in our cell model may 
have undergone some form of mutation that has left it 
constitutively activated with the subsequent loss of β1-
integrin, or TG2-induced activation of Src is tumour 
specific. TG2 may therefore play both extracellular and 
intracellular roles in Wnt signalling [44, 47, 48] which are 
key to the EMT process in the SW620 cells. Whether this 
is through its transamidation activity or via its GTPase or 
protein binding activity is not know at the moment since 
reaction of TG2 with 1-155 is likely to affect all these 
functions by inactivating the active site Cys277 and at the 
same time locking the enzyme into its open conformation 
[24]. However the absence or low expression of integrins 
in SW620 cells may diminish the extracellular role for 
TG2, as TG2-FN-integrin interraction has been reported 
to be essential for cell adhesion, migration and invasion in 
epidermoid carcinoma cell line A-431 [49].
Figure 8D shows a possible mechanism in which 
extracellular and intracellular TG2 may perturb β-catenin 
ubiquitination allowing for its cytosolic accumulation 
and subsequent translocation into the nucleus. Nuclear 
accumulation of β-catenin has been associated with cancer 
stem cells in colon and head and neck squamous cell 
carcinoma cells [50]. In a similar fashion, TG2 has been 
shown to facilitate a stem cell phenotype in epidermal 
squamous carcinoma [38], ovarian [17] and breast cancer 
cells [51] potentiating compact tumour spheroid formation 
in anchorage-independent cell culture. Our current study 
shows that the high TG2 expressing metastatic SW620 has 
the ability to form spheroids in non-adherent cell culture. 
TG2 knockdown or inactivation in these cells reduced this 
ability to form spheroids. Ectopic expression of TG2 in 
RKO cells resulted in increased clonogenic potential in 
the soft agar assay. However, it is not surprising that in 
RKO and SW480 cells TG2 manipulation did not lead to 
spheroid formation as reported previously [3].
Characterisation of the SW620 spheroids indicated 
TG2 was upregulated in the spheroid cells compared 
to cells grown in monolayer, in agreement with Cao et 
al. [17] in ovarian cancer cells where cells also showed 
increased stem cell characteristics CD44+/CD117+. The 
TG2 enriched SW620 spheroids had a 2-fold higher 
expression of CD44 when compared to monolayer cells. 
Additionally, SW620 spheroids exhibited increased 
expression of β-catenin compared to monolayers cells 
suggesting that TG2 and β-catenin may be necessary in 
cancer stem cell formation [50]. More recent studies also 
suggest that the self-renewal capacity of cancer stem cells 
in colon and head and neck cancer cells was blocked by 
perturbation of the interaction between β-catenin and 
the transcription factor TCF4 in the nucleus [52]. This 
supports our current notion in SW620 cells where TG2 
plays a role in inhibiting β-catenin ubiquitination and thus 
facilitates accumulation of β-catenin in the nucleus where 
it can interact with TCF4, enhancing the self-renewal and 
enhancing cancer stem cell capacity, a process that can be 
perturbed by inhibiting TG2.
CONCLUSIONS
TG2 expression correlates with CRC disease 
progression in vitro, and plays a key role in EMT, 
either extracellularly or intracellularly in a cell type 
specific context via multiple mechanisms. Importantly 
the TG2 selective small molecule active site directed 
inhibitor 1-155 developed in our group was able 
to attenuate TG2’s capability in inducing EMT. 
Furthermore, spheroid containing colon stem cell like 
cells demonstrated high TG2 expression and irreversible 
inhibition of TG2 by 1-155 reduced the cancer stem 
cell potential of CRCs. TG2 could be both a potential 
prognostic marker and therapeutic target for the 
treatment of colon cancer. Importantly, small molecule 
inhibitors that selectively target TG2 as demonstrated in 
this manuscript could be potential therapeutic agents for 
colon cancer treatment.
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MATERIALS AND METHODS
Reagents and antibodies
Peptidomimetic cell-permeable TG2-selective 
inhibitor 1-155 [24], and the TG2 inhibitor R283 [25] were 
synthesized in house. Chemicals were purchased from 
Sigma-Aldrich (Dorset, UK), unless stated below. The 
antibodies used in this work were listed in Supplementary 
Table 1.
Cells and cell culture
Human colorectal cancer (CRC) cell lines RKO, 
SW480 and SW620, a kind gift from Dr Chris Tselepsis 
(University of Birmingham, Birmingham, UK), were 
cultured in Dulbecco’s Modified Eagles Medium (DMEM) 
(Lonza, Cologne, Germany) containing 10% FBS (Fisher, 
Hempstead, UK), 1% (v/v) nonessential amino acids 100 U/
ml penicillin and 100 μg/ml streptomycin, unless otherwise 
indicated in a humidified atmosphere with 5% CO2 at 37
oC. 
Enrichment of spheroid cells with stem like characteristics 
was performed by culturing cells on poly-hema coated 
low attachment plates, cells were cultured in serum free 
DMEM/F12 (1:1) (Lonza, Cologne, Germany) containing 
2% serum free supplement B27 (Fisher, Hempstead, UK), 
20 ng/ml Epithelial growth factor (EGF), 0.4% bovine 
serum albumin and 4 μg/ml insulin. Spheroid cells were 
cultured in humidified atmosphere with 5% CO2 at 37
oC.
CRCs were treated with the TG2 selective cell-
permeable inhibitor 1-155 [26] at 1 µM. CRCs were also 
treated with recombinant human (rh) TGFβ1 (2.5 ng/ml) 
(R&D Systems, Minneapolis, UK) or mouse anti-human 
TGFβ neutralising antibody (R&D Systems, Minneapolis, 
UK). Control cells were treated with treatment vehicle 
DMSO or PBS. All treatments were for 48 h unless 
otherwise indicated.
Lentiviral transduction
In order to ectopically express or silence TG2 in 
CRCs, lentiviral constructs containing wild type (wt) TG2 
or different shRNA’s (Sigma-Aldrich, Dorset, UK) that 
target human TG2 were used to transduce the CRCs and 
allow optimisation of TG2 knock down by Wang et al. 
[53]. Comparison of wt cells with empty vector transduced 
control cells indicated no differences in the expression of 
TG2 or EMT markers Supplementary Figure 4.
shRNA sequences:  5’-CCACCCACCATATTGTTT 
GAT- 3’
5’-ACAGCAACCTTCTCATC 
GAGT-3’
Western blotting
SDS-PAGE and western blotting was performed by 
using specific antibodies as described previously, while the 
membranes were re-probed with GAPDH as the loading 
control [53, 54]. Signals were detected using the SynGene 
system. Densitometry was performed using the ImageJ 
software. Ratios indicate band intensity normalised to 
GAPDH from at least 2 separate experiments.
Co-immunoprecipitation (co-IP)
Following appropriate treatment, CRC cells were 
lysed in the co-IP buffer [50mM Tris-HCl containing 
0.25% sodium deoxycholate, 150 mM NaCl, 0.1 mM 
phenylmethylsulfonyl fluoride, 1% (v/v) proteinase inhibitor 
cocktail and 500 µM TG inhibitor R283 as described 
previously] [19]. Cell lysates (600 µg) were pre-cleared 
by incubating with 50 µl of protein A or G-Sepharose bead 
slurry (GE Healthcare, Buckinghamshire, UK) at 4°C for 90 
min. Following incubation with 0.5 µg of primary antibody 
for 90 min at 4°C, the samples were incubated with 50 µl 
of Protein A or G Sepharose bead slurry for 2 h at 4°C. The 
immunocomplex was collected in 30 µl Laemmli buffer and 
used for Western blotting analysis.
Dot blotting
Total number of 2.5×105 cells were seeded in 
complete growth media for 4 h. After which the complete 
growth media was replaced with ITS supplemented serum 
free cell culture media, cells were incubated for 16-18 
h and the cell culture media was collected and the dot 
blotting and Western blotting for the presence of TGFβ 
was performed as described previously [54].
Immunofluorescence (IF)
IF staining was performed as previously described 
by Wang et al. [53], following plating of cells on chamber 
slides. Fluorescent Images were visualized and captured 
using an epifluorescent microscope.
TG2 activity assay
The transglutaminase activity of TG2 was measured 
via biotin-cadaverine incorporation into FN as described 
previously [11]. The incorporated biotin-cadaverine 
was then revealed using Extravidin-peroxidase. The 
development of colour was terminated using 3 N HCl and 
the absorbance was read at 490 nm using a Spectrafluor 
plate reader.
Cell surface TG activity was measured by incubating 
live cells (2×104 /well) with 0.1 mM biotin-cadaverine in 
serum free medium on FN-coated wells at 37°C for 2 h as 
described by Jones et al. [22].
Detection of secreted TGFβ1 by ELISA
Secreted TGFβ1 was measured by ELISA following 
the manufacturer’s instructions (Novex™, Fisher, 
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Hempstead, UK). Briefly, CRCs were seeded into 24-well 
plates and allowed to adhere for 4 h in complete medium. 
Complete media was replaced with growth factor-free ITS 
replacement medium. Following 16 h incubation with the 
cells, the culture medium was collected for analysis.
Soft agar assay
The “Soft agar assay” was performed to assess 
colony formation and anchorage independent proliferation 
according to the method of Akagi et al [55]. Cultures 
were maintained in a humidified incubator at 37°C and 
5% CO2 for 2 weeks before colonies were counted and 
photographed.
Statistics
Data were expressed as mean ± S.D. The data shown 
are derived from a representative experiment undertaken 
in triplicate (unless otherwise stated). Comparisons among 
different groups were performed by analysis of variance 
using one-way ANOVA using the GraphPad Instat software 
package. Significant differences between control and 
treatment groups were analysed by Bonferroni’s Multiple 
Comparison Test. Statistical significant difference between 
data sets was defined in the text by p < 0.05 (two-sided).
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